|1.||Kyprianou, Natasha: 14 articles (05/2011 - 01/2002)|
|2.||Davis, Barry R: 10 articles (12/2012 - 09/2002)|
|3.||ALLHAT Collaborative Research Group: 8 articles (11/2009 - 02/2001)|
|4.||Kaplan, Steven A: 7 articles (12/2015 - 12/2003)|
|5.||Black, Henry R: 7 articles (05/2009 - 01/2002)|
|6.||Kusek, John W: 6 articles (06/2014 - 12/2003)|
|7.||Kirby, R S: 6 articles (01/2005 - 07/2000)|
|8.||Roehrborn, Claus G: 5 articles (09/2008 - 12/2003)|
|9.||Kyprianou, N: 5 articles (05/2003 - 01/2000)|
|10.||Michel, Martin C: 4 articles (09/2014 - 01/2006)|
|1.||Hypertension (High Blood Pressure)
08/16/1989 - "This unique combination of antihypertensive efficacy and favorable effect on blood lipid levels indicates that once-daily treatment with doxazosin holds considerable promise in the treatment of hypertension, both from the point of view of its antihypertensive efficacy and also from its primary preventative potential."
05/01/2000 - "These findings demonstrate that doxazosin add-on therapy is an effective, well-tolerated treatment strategy for patients with inadequately controlled hypertension."
01/01/1995 - "Thus, it can be concluded doxazosin is an effective and well tolerated treatment for BPH which appears to have additional benefits in the management of patients with concomitant hypertension."
10/01/1990 - "Doxazosin was well tolerated and was shown to be effective as monotherapy in mild and moderate hypertension. "
05/29/1987 - "Doxazosin is a once-daily, long-acting, selective alpha 1-adrenergic inhibitor that is effective for the treatment of essential hypertension. "
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
06/10/2005 - "These findings, that demonstrate chronic doxazosin administration causes significant changes in the expression of several hundred genes in the rat prostate, may provide insight into the long-term efficacy of alpha1-AR antagonists in the treatment of benign prostatic hyperplasia."
01/01/2015 - "To compare the efficacy of 4 mg and 8 mg doxazosin XL treatments in patients with benign prostatic hyperplasia-related lower urinary tract symptoms and determine the efficiency of 8 mg in those patients with inadequate response to 4 mg. A total of 162 patients were included in this study. "
09/01/1996 - "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies."
03/01/1994 - "In a placebo-controlled study, the safety and efficacy of the selective alpha 1-adrenoceptor-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia (BPH) were evaluated. "
01/01/1993 - "The safety and efficacy of the selective alpha 1-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia were evaluated in a randomized, double-blind and placebo-controlled 9-week study of 100 patients. "
07/01/2001 - "I've been taking Cardura and it's helped a lot, but my doctor stopped it because he said a study found the drug could cause heart failure. "
08/01/2009 - "Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients."
09/01/2010 - "Furthermore, use of doxazosin in ASCOT was not associated with an increased risk of heart failure, in contrast to the earlier finding of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). "
10/01/2005 - "A double-blind, randomized study was conducted on 30 patients with chronic congestive heart failure (NYHA III-IV), with cardiac index<2.5 l/minxm, and/or with pulmonary capillary wedge pressure>16 mm Hg. Of the 30 patients, 15 were treated with doxazosin and 15 with placebo, both adjuvant to stable oral therapy, which included a minimum of an ACE inhibitor and a diuretic. "
04/01/2001 - "The doxazosin arm of the ALLHAT study was terminated by the data monitoring and safety board because the doxazosin-treated patients developed congestive heart failure at a greater rate than diuretic-treated patients. "
11/01/2009 - "In this study we aimed to evaluate the impact of doxazosin treatment on erectile functions in patients with lower urinary tract symptoms (LUTS) and having erectile dysfunction (ED) at baseline. "
03/01/2015 - "With doxazosin, the incidence was 5.8% vs. 3.3% for erectile dysfunction, 3.6% vs. 1.9% for reduced libido and 0.4% vs. 1.4% for ejaculatory disorders. "
09/01/2011 - "Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms."
01/01/2005 - "To report a comprehensive retrospective analysis of the favourable effects of doxazosin extended-release (XL) and doxazosin standard on the sexual health of patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED), augmenting a previous study of 680 patients with symptomatic BPH. "
09/01/2008 - "Patients with benign prostatic hyperplasia and erectile dysfunction treated with the doxazosin gastrointestinal therapeutic system on a regular basis, with no other antihypertensive events, were recruited. "
01/01/2002 - "A total of 60 men with chronic non-bacterial prostatitis were randomised to daily supplement of 4 mg doxazosin or a placebo, for 3 months. "
01/01/2002 - "The efficacy of doxazosin monotherapy in chronic non-bacterial prostatitis was investigated in terms of urinary symptom, pain and quality of life assessment versus placebo. "
01/01/2002 - "Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo."
01/01/2008 - "For a 6-week short-term treatment levofloxacin is more effective than doxazosin for chronic prostatitis/chronic pelvic pain syndrome. "
01/01/2008 - "We performed a prospective, randomized study to examine the efficacies of levofloxacin and doxazosin alone and as a combination therapy in patients with National Institutes of Health (NIH) category III chronic prostatitis/chronic pelvic pain syndrome. "
|7.||Adrenergic Antagonists (Antiadrenergic Agents)
|9.||Antihypertensive Agents (Antihypertensives)
|3.||Psychology Biofeedback (Biofeedback)
|5.||Prostatectomy (Retropubic Prostatectomy)